8-K: McKesson Reports Strong Q3 Results, Raises Full-Year Adjusted EPS Guidance

McKesson Corporation announced robust third-quarter results, driven by revenue growth and strategic initiatives, leading to an increased and narrowed adjusted earnings per diluted share guidance for fiscal year 2025.

Summary

• McKesson Corporation reported an 18% increase in consolidated revenues, reaching $95.3 billion for the third quarter ended December 31, 2024.
• Earnings per diluted share increased by $2.53 to $6.95, while adjusted earnings per diluted share rose by 4% to $8.03.
• The company has raised and narrowed its adjusted earnings per diluted share guidance for fiscal year 2025 to a range of $32.55 to $32.95, indicating a 19% to 20% growth compared to the prior year.
• McKesson signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC, aiming to develop a leading platform for retinal care.
• The company completed the sale of its Canada-based Rexall and Well.ca retail businesses on December 30, 2024.
• For the first nine months of the fiscal year, McKesson returned $3.1 billion of cash to shareholders, including $2.8 billion in common stock repurchases and $254 million in dividend payments.
• During the first nine months of the fiscal year, McKesson used cash from operations of $1.7 billion, and invested $581 million in capital expenditures, resulting in negative Free Cash Flow of $2.2 billion.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, increased guidance, and strategic acquisitions. While there are some negative aspects, the overall tone is optimistic and suggests confidence in the company's future performance.

Positives

• Strong revenue growth of 18% driven by the U.S. Pharmaceutical segment, including increased prescription volumes and growth in the oncology platform.
• Adjusted Operating Profit growth of 16%.
• The acquisition of PRISM Vision Holdings, LLC, is expected to strengthen McKesson's position in community practice management and specialty solutions, particularly in retinal care.
• The sale of Rexall and Well.ca retail businesses was completed, streamlining McKesson's portfolio.
• McKesson returned $3.1 billion to shareholders through share repurchases and dividends.
• Lynne Doughtie and Dr. Julie Gerberding were elected as New Directors, adding expertise in accounting, finance, healthcare, and public policy.

Negatives

• Net income attributable to McKesson Corporation decreased by 8% year-to-date.
• Negative Free Cash Flow of $2.2 billion for the first nine months of the fiscal year.
• Medical-Surgical Solutions Segment revenues decreased by 3%, driven by lower contributions from illness season vaccines and testing in the primary care channel.

Risks

• The company acknowledges risks and uncertainties that could cause actual results to differ materially from forward-looking statements, including legal disputes, regulatory changes, cybersecurity incidents, and economic factors.
• McKesson is subject to frequently changing, extensive, complex, and challenging healthcare and other laws.
• The company might be adversely impacted by regulatory delays or other difficulties with acquisitions or divestitures.
• McKesson might be harmed by changes in relationships or contracts with suppliers.
• The company might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.

Future Outlook

McKesson is raising and narrowing its fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.55 to $32.95 from the previous range of $32.40 to $33.00.

Management Comments

• Brian Tyler, chief executive officer, stated that McKesson reported strong third quarter operational results with broad-based Revenue growth of 18% and Adjusted Operating Profit growth of 16%.
• Mr. Tyler added that the company remains committed to its enterprise growth strategy, including growth pillars within oncology and biopharma services.
• Mr. Tyler also mentioned the signing of a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, in support of McKesson's leadership in community practice management and specialty solutions.

Industry Context

McKesson's acquisition of PRISM Vision Holdings reflects a broader trend in the healthcare industry towards consolidation and specialization, particularly in high-growth areas like retinal care. This move positions McKesson to leverage its existing expertise in practice management and clinical research to serve a growing market.

Comparison to Industry Standards

• McKesson's revenue growth of 18% in Q3 is strong compared to peers in the pharmaceutical distribution industry, such as Cardinal Health and AmerisourceBergen.
• The adjusted EPS growth of 4% is solid, but investors will likely focus on the raised full-year guidance as a key indicator of future performance.
• The acquisition of PRISM Vision Holdings is similar to other strategic moves by industry players to expand into specialized healthcare services, such as UnitedHealth Group's Optum division.

Management Changes

Stakeholder Impact

• Shareholders will likely react positively to the strong financial results and increased guidance.
• Employees may feel more secure due to the company's growth and strategic initiatives.
• Customers may benefit from McKesson's expanded services and solutions, particularly in specialized areas like retinal care.
• Suppliers may see increased business opportunities as McKesson continues to grow.
• Creditors may view McKesson as a more creditworthy borrower due to its strong financial performance.

Next Steps

• McKesson will hold a conference call on February 5th to discuss the financial results.
• McKesson management will participate in the TD Cowen 45th Annual Healthcare Conference on March 4, 2025.

Key Dates